Financial News Feed

Today VRNA ranks # as BUY CANDIDATE.
Today VRNA ranks # as BUY CANDIDATE.

VRNA stock Verona Pharma plc

VRNA stock
Verona Pharma plc

Zacks Investment Research upgraded shares of VERONA PHARMA P/S (NASDAQ:VRNA) from a hold rating to a buy rating in a report issued on Thursday morning. The firm currently has $6.75 target price on the...

Read more

Verona Pharma Plc - American Depositary Share (NASDAQ:VRNA) had an increase of its short interest by 1.85%. FINRA announced in March VRNA's total 11,000 short...

Read more

Zacks Investment Research downgraded shares of VERONA PHARMA P/S (NASDAQ:VRNA) from a buy rating to a hold rating in a report issued on Wednesday morning. According to Zacks, “Verona Pharma plc is a...

Read more

VERONA PHARMA P/S (NASDAQ:VRNA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Wednesday. According to Zacks, “Verona Pharma plc i...

Read more

Wall street brokerage firm analysts are offering a consensus “Buy” rating on shares of Verona Pharma plc (:VRNA). Using the following ratings scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell and...

Read more

Both TCR2 Therapeutics Inc. (NASDAQ:TCRR) and Verona Pharma plc (NASDAQ:VRNA) are each other’s competitor in the Biotechnology industry. Thus the contrast of their dividends, institutional ownership...

Read more

Watching some technical levels for Verona Pharma Plc ADR (VRNA), we have noticed that the current 20-Day Bollinger Bands signal is reading Hold. This indicator may be used to assist with identifying o...

Read more

Both Orchard Therapeutics plc (NASDAQ:ORTX) and Verona Pharma plc (NASDAQ:VRNA) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to analy...

Read more

Tracking medium-term indicators on shares of Verona Pharma Plc ADR (VRNA), we have noted that the reading from the 40-day commodity channel index is currently Hold. The CCI indicator is primarily used...

Read more

The following slide deck was published by Verona Pharma plc in conjunction with this event....

Read more

Investors may be watching indicator signals on shares of Verona Pharma Plc ADR (VRNA). After a recent look, we have noted that the beta research opinion is currently Buy. This signal uses a system com...

Read more

As Biotechnology businesses, Verona Pharma plc (NASDAQ:VRNA) and DiaMedica Therapeutics Inc. (NASDAQ:DMAC), are affected by compare. This especially applies to their profitability, analyst recommendat...

Read more

Checking in on the 50-day moving average vs price signal for Verona Pharma Plc ADR (VRNA), we have noted that the current reading is Sell. We have also taken note of the present signal strength which ...

Read more

Brokerages expect VERONA PHARMA P/S (NASDAQ:VRNA) to announce ($0.57) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for VERONA PHAR...

Read more

Equities research analysts expect VERONA PHARMA P/S (NASDAQ:VRNA) to post earnings per share of ($0.57) for the current quarter, according to Zacks. Zero analysts have issued estimates for VERONA PHAR...

Read more

News Feed powered by

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank